Valneva: sharp reduction in 9m losses
(CercleFinance.com) - Valneva reported an adjusted net loss of 99.
1 million euros for the first nine months of 2022, compared to 245.9 million euros for the same period last year, while its adjusted EBITDA loss fell from 227.6 million euros to 38 million euros.
The vaccine company's total revenue was 249.9 million euros in the nine months to 30 September, an almost 3.5-fold increase over 2021, driven mainly by non-product revenues.
They benefited from the recognition of revenues from previous Covid-19 vaccine supply contracts, while non-Covid-19 product sales grew by double digits (+11.2%).
Copyright (c) 2022 CercleFinance.com. All rights reserved.